Degarelix clinical trials
Also written Firmagon, FE200486 and ASP3550.
How each study uses degarelix is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the degarelix studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 24 Dec 2008 · FIRMAGON · NDA 022201 (FDA, Drugs@FDA)
- European Union
- 17 Feb 2009 · Firmagon · EMEA/H/C/000986 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
80 studies that test it; most in 2012 (11)
| Year | Studies |
|---|---|
| 2001 | 2 |
| 2002 | 3 |
| 2003 | 1 |
| 2004 | 2 |
| 2005 | 3 |
| 2006 | 2 |
| 2007 | 4 |
| 2008 | 2 |
| 2009 | 7 |
| 2010 | 5 |
| 2011 | 2 |
| 2012 | 11 |
| 2013 | 4 |
| 2014 | 3 |
| 2015 | 7 |
| 2016 | 2 |
| 2017 | 5 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 4 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 4 |
| 2024 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 40 · Other 41
Ferring Pharmaceuticals (37) · Memorial Sloan Kettering Cancer Center (6) · Astellas Pharma Inc (3) · Centre for Endocrinology and Reproductive Medicine, Italy (2) · British Columbia Cancer Agency (2) · Rabin Medical Center (2) · University Health Network, Toronto (2) · The University of Texas Health Science Center, Houston (2)
Often tested with
Tested in the same studies.
Leuprolide (9) · Triptorelin (7) · Goserelin (6) · Bicalutamide (5) · Docetaxel (4) · Darolutamide (3) · Abiraterone Acetate (3) · Abiraterone (3)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3, 1 in phase 3
Studies that test degarelix, phase 3 first.
- Nov 2026Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance TrialPhase 3 · NRG Oncology
- Dec 2026Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell TransplantationPhase 2 · Memorial Sloan Kettering Cancer Center
- Apr 2027ETHAN - ET for Male BCPhase 2 · Jose Pablo Leone
Studies
Open first, then newest update. How each study uses degarelix is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 81
- ETHAN - ET for Male BCRecruitingPhase 2Jose Pablo LeoneNCT05501704Written as DegarelixHow we know
- Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CTRecruitingPhase 2Baptist Health South FloridaNCT07455903Written as DegarelixHow we know
- Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular TracersRecruitingPhase 2/3Cancer Research AntwerpNCT06282588Written as Firmagon 120 MG InjectionHow we know
- Study of Radiation Therapy in Combination With Darolutamide + Degarelix in Intermediate Risk Prostate CancerNot yet recruitingPhase 2University Health Network, TorontoNCT04176081Written as DegarelixHow we know
- Neoadjuvant ADT With TULSA in the Treatment of Intermediate Risk Prostate CancerActive, not recruitingPhase 1Turku University HospitalNCT05917860Written as DegarelixHow we know
- Efficacy Study of Switching to a Lutenizing Hormone-releasing Hormone (LHRH) Antagonist From a LHRH Agonist to Treat Progressive Castrate Resistant Prostate Cancer (CRPC)WithdrawnPhase 2British Columbia Cancer AgencyNCT01630967Written as DegarelixHow we know
- TRial on the Endocrine Activity of Neoadjuvant DegarelixCompletedPhase 2ETOP IBCSG Partners FoundationNCT02005887Written as degarelixHow we know
- Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance TrialActive, not recruitingPhase 3NRG OncologyNCT05050084Written as DegarelixHow we know
- Androgen Deprivation Therapy Prior to Prostatectomy for Patients With Intermediate and High Risk Prostate CancerCompletedNot applicableMemorial Sloan Kettering Cancer CenterNCT01542021Written as degarelix injectionHow we know
- Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical ProstatectomyCompletedPhase 2Memorial Sloan Kettering Cancer CenterNCT02020070Written as DegarelixHow we know
- High-Dose Brachytherapy in Treating Patients With Prostate CancerCompletedNot applicableStanford UniversityNCT02346253Written as DegarelixHow we know
- Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate CancerActive, not recruitingPhase 3European Organisation for Research and Treatment of Cancer - EORTCNCT02799706Written as DegarelixHow we know
- Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate CancerActive, not recruitingPhase 2City of Hope Medical CenterNCT03361735Written as DegarelixHow we know
- Targeting Androgen Signaling in Urothelial Cell Carcinoma - NeoadjuvantTerminatedPhase 1Brown UniversityNCT05839119Written as DegarelixHow we know
- Efficacy and Tolerance of an Ovarian Stimulation Protocol Combining Follicle Stimulating Hormone (FSH) and Degarelix Acetate in Female Candidates for Fertility Preservation Before Chemotherapy for Breast CancerCompletedPhase 2Assistance Publique - Hôpitaux de ParisNCT03947151Written as Degarelix injection(s)How we know
- Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell TransplantationActive, not recruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT01746849Written as DegarelixHow we know
- Extension Study Investigating the Long-Term Safety of Degarelix One-Month Depots in Patients With Prostate CancerCompletedPhase 2/3Ferring PharmaceuticalsNCT00117286Written as DegarelixHow we know
- Phase II Study of Docetaxel Before Degarelix in Patients With Newly Diagnosed Metastatic Prostate Cancer.CompletedPhase 2Medical University of South CarolinaNCT03069937Written as DegarelixHow we know
- Interest of PET-PSMA Imaging Potentialised by Androgen Blockade in Localized Prostatic AdenocarcinomaCompletedPhase 2Centre Leon BerardNCT04391556Written as FirmagonHow we know
- A Study of Degarelix in Taiwanese Patients With Prostate CancerCompletedPhase 3Ferring PharmaceuticalsNCT01220869Written as DegarelixHow we know
See all 81 studies that test degarelix →
Given beside what is tested · 28 — degarelix is usual care or a partner of the new treatment
- Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET ImagingRecruitingPhase 3ECOG-ACRIN Cancer Research GroupNCT04423211Written as DegarelixHow we know
- NeoAdjuvant Theranostic Lutetium Study: The Nautilus TrialRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT06066437Written as Arm B: 177Lu rhPSMA-10.1 plus DegarelixHow we know
- Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate CancerRecruitingPhase 2M.D. Anderson Cancer CenterNCT05873192Written as DegarelixHow we know
- Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate CancerRecruitingPhase 3SWOG Cancer Research NetworkNCT03678025Written as DegarelixHow we know
- Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate CancerRecruitingPhase 2City of Hope Medical CenterNCT04734730Written as DegarelixHow we know
- Cardiometabolic Consequences of the Loss of Ovarian FunctionRecruitingPhase 4University of Colorado, DenverNCT06264882Written as DegarelixHow we know
- Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by SurgeryActive, not recruitingPhase 2/3NRG OncologyNCT03070886Written as DegarelixHow we know
- Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate CancerActive, not recruitingPhase 2/3VA Office of Research and DevelopmentNCT04787744Written as Degarelix & RelugolixHow we know
- Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8)CompletedPhase 1/2Mark SteinNCT03689699Written as DegarelixHow we know
- Neo-DAB: Darolutamide and Abemaciclib in Prostate CancerTerminatedPhase 1Praful Ravi, MB BCHir, MRCPNCT05617885Written as DegarelixHow we know
- A Study of BMS986365 in Combination With Degarelix in People With Prostate CancerActive, not recruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT07335796Written as DegarelixHow we know
- Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate CancerActive, not recruitingPhase 1/2University of Wisconsin, MadisonNCT04989946Written as DegarelixHow we know
- Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT TrialActive, not recruitingPhase 3NRG OncologyNCT04513717Written as DegarelixHow we know
- Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate CancerActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT01786265Written as DegarelixHow we know
- A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation TherapyActive, not recruitingPhase 3Alliance for Clinical Trials in OncologyNCT04455750Written as DegarelixHow we know
- Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate CancerActive, not recruitingPhase 2Jonsson Comprehensive Cancer CenterNCT01990196Written as degarelixHow we know
- Non-fucosylated Anti-CTLA-4 (BMS-986218) + Degarelix Acetate vs. Degarelix Acetate Alone in Men With High-risk Localized Prostate CancerCompletedEarly Phase 1Columbia UniversityNCT04301414Written as BMS-986218 and DegarelixHow we know
- REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate CancerActive, not recruitingPhase 2Mark SteinNCT03951831Written as DegarelixHow we know
- Neoadjuvant Degarelix With or Without Apalutamide (ARN-509) Followed by Radical ProstatectomyActive, not recruitingPhase 2Universitaire Ziekenhuizen KU LeuvenNCT03080116Written as DegarelixHow we know
- Pilot Trial of Chemohormonal Therapy Followed by Prostatectomy in High Risk Prostate CancerCompletedEarly Phase 1University of Wisconsin, MadisonNCT03358563Written as DegarelixHow we know
Showing 20 of 28.
As the comparator · 5 — what is tested is compared with degarelix
- Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE TrialRecruitingPhase 2Mayo ClinicNCT06378866Written as DegarelixHow we know
- Radiotherapy Combined With a LHRH (Ant)Agonist Versus Apalutamide in Patients With Biochemical Recurrence After RPRecruitingPhase 2Cancer Research AntwerpNCT03899077Written as Degarelix acetateHow we know
- Non-fucosylated Anti-CTLA-4 (BMS-986218) + Degarelix Acetate vs. Degarelix Acetate Alone in Men With High-risk Localized Prostate CancerCompletedEarly Phase 1Columbia UniversityNCT04301414Written as BMS-986218 and DegarelixHow we know
- Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate CancerCompletedPhase 2University of Colorado, DenverNCT02278185Written as degarelixHow we know
- Safety and Efficacy of TAK-385 for Patients With Localized Prostate CancerCompletedPhase 2Millennium Pharmaceuticals, Inc.NCT02135445Written as DegarelixHow we know
Codes
What other systems call degarelix · ClinicalTrials.gg INT004362
- UNII (FDA) SX0XJI3A11DEGARELIXConfirmed FDA, Wikidata
- RxNorm 475230Confirmed FDA, Wikidata
- Wikidata Q1182795degarelixConfirmed FDA, Wikidata
- NCI Thesaurus C48385DegarelixConfirmed FDA, Wikidata
- DrugBank DB06699One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | SX0XJI3A11 | DEGARELIX | Confirmed FDA, Wikidata |
| RxNorm | 475230 | — | Confirmed FDA, Wikidata |
| Wikidata | Q1182795 | degarelix | Confirmed FDA, Wikidata |
| NCI Thesaurus | C48385 | Degarelix | Confirmed FDA, Wikidata |
| DrugBank | DB06699 | — | One source Wikidata |
Also registered as degarelix acetate (UNII I18S89P20R · RxNorm 835863).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.